drugset / Trial / NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2029-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Itraconazole | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sofetabart Mipitecan | Unknown | — | Intravenous |